It may be attributed to a relative short term of follow-up, insufficient case number or non-molecular preselection, since reports have shown that TKIs mostly benefit NSCLC patients with driver (such as EGFR) mutations48, 49 and ICIs usually take a longer time to be clinically effective50. Here, EGFR is linked to non-small cell lung carcinoma.